Method for constructing human mononuclear cell line for expressing NLRP3 CAPS patient mutant and application of human mononuclear cell line

The construction of an inducible THP-1 cell line expressing NLRP3 mutants addresses limitations in current CAPS treatments by enabling efficient drug screening and regulatory factor identification, stabilizing mutant expression and improving treatment outcomes.

CN119060957APending Publication Date: 2024-12-03INST PASTEUR OF SHANGHAI CHINESE ACADEMY OF SCI
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310651431.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-06-02
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

Current treatments for NLRP3-related diseases, such as CAPS, are limited by the need for injectable drugs with short half-lives, potential side effects, and the inability to target IL-18 and HMGB1 pathways beyond IL-1β, necessitating the development of small molecule inhibitors and efficient screening methods.

Method used

A method for constructing an inducible THP-1 cell line expressing a NLRP3 mutant protein using a lentiviral vector, allowing for high-throughput screening of drugs targeting NLRP3 and regulating inflammasome activation.

Benefits of technology

Enables stable expression of NLRP3 mutants in THP-1 cells, facilitating effective drug screening and identification of regulatory factors for NLRP3-related diseases, reducing the need for patient samples and improving treatment efficacy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0004268502200000011
    Figure HDA0004268502200000011
  • Figure HDA0004268502200000012
    Figure HDA0004268502200000012
  • Figure HDA0004268502200000021
    Figure HDA0004268502200000021
Patent Text Reader

Abstract

The invention provides a method for constructing a human monocyte line for expressing an NLRP3CAPS patient mutant and application of the human monocyte line. Specifically, the invention provides a method for constructing a genetically engineered cell for inducible expression of NLRP3 mutant protein, the genetically engineered cell constructed by the method, and an application of the genetically engineered cell, such as high-throughput screening of targeted NLRP3 on a cellular level to treat drugs such as inflammatory diseases, such as drugs for treating inflammatory diseases, and the like. And screening regulatory factors participating in regulation and control of NLRP3 inflammasome activation. The method and application have important clinical significance in the field of treatment of NLRP3 related diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biotechnology, and more specifically to a method for constructing a human monocyte cell line expressing an NLRP3 CAPS patient mutant and its application. Background Art

[0002] NLRP3 inflammasome (NOD-, LRR-and pyrin domain-containing 3inflammasome) is a multi-protein complex located in cells. Using knockout mice as a model, it was found that NLRP3 inflammasome plays beneficial or harmful functions in a variety of infectious, metabolic imbalance and autoimmune diseases. Importantly, a series of gain-of-function gene mutations of NLRP3 can lead to cold and heat cycle associated syndrome (CAPS).

[0003] Cryopyrin-associated periodic syndrome (CAPS) is a rare autosomal dominant genetic disease with an incidence of about 1 in 300,000 to 500,000 people. CAPS is a general term for autoinflammatory disorders caused by abnormal activation of the NLRP3 gene encoding mutations. NLRP3-related mutations in CAPS patients lead to excessive activation of the NLRP3 gene, thereby inducing the body to produce a large number of pro-inflammatory cells IL-1β, leading to inflammatory symptoms.

[0004] At present, blocking the IL-1 signaling pathway is considered to be the most effective method for treating NLRP3-related diseases. There are three drugs that block the IL-1 signaling pathway approved by the US FDA for the treatment of inflammatory diseases, namely anakinra, rilonacept and canakinumab. Despite this, blocking the IL-1 signaling pathway still has many shortcomings in the treatment of NLRP3-related diseases. First of all, in addition to IL-1β, the factors that induce secretion by NLRP3 inflammasome activation include IL-18, HMGB1, etc. In addition, a large amount of cell pyroptosis will be produced downstream of inflammasome activation, and blocking the IL-1β signaling pathway has no effect on these pathways. Secondly, all three drugs need to be administered by injection. Anakinra needs to be administered repeatedly due to its short half-life, which can easily cause inflammation at the injection site, increase the risk of infection with other microorganisms, and increase patient pain. In addition, as a protein drug, the high price also increases the burden of patient treatment.

[0005] Therefore, there is an urgent need to develop small molecule inhibitors targeting NLRP3 in this field, and also to develop corresponding efficient screening methods. The screening and development of NLRP3 small molecule drugs has important clinical significance. Summary of the invention

[0006] The purpose of the present invention is to provide a method for efficiently screening small molecule drugs targeting NLRP3.

[0007] Another object of the present invention is to provide an inducible expression K355T THP-1 cell line and a construction method thereof, wherein the cell line can be used for high-throughput screening of drugs targeting NLRP3 for the treatment of inflammatory diseases, and for screening regulatory factors involved in regulating NLRP3 inflammasome activation.

[0008] In a first aspect of the present invention, a method for constructing a genetically engineered cell that can induce expression of a NLRP3 mutant protein is provided, the method comprising the steps of:

[0009] (i) providing an inducible viral vector and transfecting packaging cells, wherein the inducible viral vector comprises a coding sequence for a NLRP3 mutant protein;

[0010] (ii) isolating and / or purifying the obtained viral particles from the culture of said packaging cells; and

[0011] (iii) using the viral particles to infect host cells, thereby obtaining the genetically engineered cells, wherein the endogenous NLRP3 gene of the host cells is knocked out;

[0012] Furthermore, the NLRP3 mutant protein is a NLRP3 gain-of-function mutant protein.

[0013] In another preferred embodiment, the inducible viral vector is a lentiviral vector.

[0014] In another preferred embodiment, the lentiviral vector is a Tet-On PLVX lentiviral vector.

[0015] In another preferred embodiment, the inducible viral vector is expressed by induction of doxycycline or tetracycline.

[0016] In another preferred embodiment, the inducible viral vector further includes one or more of: a promoter, an enhancer, an intron, an operator, a transcription enhancing element WPRE, a long terminal repeat sequence LTR, a resistance gene, a transcription termination signal, a polyadenylation signal, a selective marker, a replication origin, a nucleic acid restriction site, a homologous recombination site, or a combination thereof.

[0017] In another preferred embodiment, the promoter includes a tissue-specific promoter, an inducible promoter, a constitutive promoter, or a combination thereof.

[0018] In another preferred embodiment, the promoter is an inducible promoter.

[0019] In another preferred example, the promoter includes: TRE3G promoter, pTet promoter, TRE promoter, CMV promoter, SV40 promoter, PGK promoter, AmpR promoter, or a combination thereof.

[0020] In another preferred embodiment, the inducible promoter is TRE3G promoter.

[0021] In another preferred embodiment, the operon is the tetracycline (tet) operon.

[0022] In another preferred embodiment, the resistance gene includes blasticidin (BSD) resistance gene and ampicillin resistance gene.

[0023] In another preferred embodiment, when the inducible viral vector is a lentiviral vector, the step (i) includes a sub-step (ia): co-transfecting the packaging cell with the inducible viral vector, a packaging plasmid, and an envelope protein plasmid.

[0024] In another preferred embodiment, the packaging plasmid is a PXA2 plasmid.

[0025] In another preferred embodiment, the envelope protein plasmid is a VSVG plasmid.

[0026] In another preferred embodiment, the packaging cells are HEK293T cells.

[0027] In another preferred embodiment, the NLRP3 mutant protein has one or more mutations in CAPS patient mutants based on the amino acid sequence of the wild-type NLRP3 protein.

[0028] In another preferred embodiment, the NLRP3 mutant protein has one or more mutations based on the amino acid sequence of the wild-type NLRP3 protein, and the mutation site is selected from the following group: position 350, position 351, position 352, position 353, position 354, position 355, or a combination thereof.

[0029] In another preferred embodiment, the mutation site is position 355.

[0030] In another preferred embodiment, the NLRP3 mutant protein has a K355T mutation based on the amino acid sequence of the wild-type NLRP3 protein.

[0031] In another preferred embodiment, the amino acid sequence of the wild-type NLRP3 protein is shown in SEQ ID NO: 1.

[0032] In another preferred embodiment, the NLRP3 mutant protein has an amino acid sequence as shown in SEQ ID NO:2.

[0033] In another preferred embodiment, the coding sequence of the NLRP3 mutant protein is shown in SEQ ID NO:3.

[0034] In another preferred embodiment, the host cell is selected from the following group: THP-1 cells, BLaER1 cells, or a combination thereof.

[0035] In another preferred embodiment, the host cell is a THP-1 cell.

[0036] In another preferred embodiment, step (iii) includes a sub-step (iiia): using a gene editing system to construct a host cell in which the endogenous NLRP3 gene is knocked out.

[0037] In another preferred embodiment, the gene editing system includes sgRNA targeting the NLRP3 gene.

[0038] In another preferred example, the coding sequence of the sgRNA is shown in SEQ ID NO:4.

[0039] In another preferred embodiment, the method further comprises step (iv): screening and / or identifying the obtained genetically engineered cells.

[0040] In another preferred embodiment, the screening includes screening based on resistance genes.

[0041] In another preferred example, the identification includes identification based on induced expression.

[0042] In a second aspect of the present invention, a genetically engineered cell is provided, wherein the genetically engineered cell is induced to express a NLRP3 mutant protein.

[0043] In another preferred embodiment, the NLRP3 mutant protein is a NLRP3 gain-of-function mutant protein.

[0044] In another preferred embodiment, the NLRP3 mutant protein has one or more mutations based on the amino acid sequence of the wild-type NLRP3 protein, and the mutation site is selected from the following group: position 350, position 351, position 352, position 353, position 354, position 355, or a combination thereof.

[0045] In another preferred embodiment, the mutation site is position 355.

[0046] In another preferred embodiment, the NLRP3 mutant protein has a K355T mutation based on the amino acid sequence of the wild-type NLRP3 protein.

[0047] In another preferred embodiment, the amino acid sequence of the wild-type NLRP3 protein is shown in SEQ ID NO: 1.

[0048] In another preferred embodiment, the NLRP3 mutant protein has an amino acid sequence as shown in SEQ ID NO:2.

[0049] In another preferred embodiment, the genetically engineered cells are selected from the following group: THP-1 cells, BLaER1 cells, or a combination thereof.

[0050] In another preferred embodiment, the genetically engineered cells are THP-1 cells.

[0051] In another preferred embodiment, the genetically engineered cells are not animal or plant species.

[0052] In another preferred embodiment, the condition for inducing expression is doxycycline-induced expression, tetracycline-induced expression, ligand-induced expression, or a combination thereof.

[0053] In another preferred embodiment, the condition for inducing expression is doxycycline-induced expression.

[0054] In another preferred embodiment, the concentration of doxycycline is 0.1-10 μg / ml, preferably 0.5-5 μg / ml, more preferably 1 μg / ml.

[0055] In another preferred embodiment, the genetically engineered cells are constructed by the method described in the first aspect of the present invention.

[0056] In a third aspect of the present invention, a method for screening NLRP3 targeted inhibitors is provided, the method comprising the steps of:

[0057] (a) providing a genetically engineered cell according to the second aspect of the present invention, and dividing the genetically engineered cell into n portions, where n is a positive integer ≥ 3 (e.g., 3-10 portions, for example, 3, 4, 5, or 6 portions);

[0058] (b) setting up a negative control group, a positive control group and a test group, and providing conditions for inducing expression;

[0059] The test conditions of the negative control group, the positive control group and the test group are the same, except that:

[0060] In the negative control group, at least one of the genetically engineered cells is co-incubated with a negative control substance;

[0061] In the positive control group, at least one of the genetically engineered cells is co-incubated with a positive control;

[0062] In the test group, at least one of the genetically engineered cells is co-incubated with a candidate substance;

[0063] (c) detecting the cell death levels of the negative control group, the positive control group and the test group; and

[0064] (d) comparing the cell death levels of the negative control group, the positive control group and the test group to determine whether the candidate substance is a NLRP3 targeted inhibitor, and / or determining the efficiency of the candidate substance in targeted inhibition of NLRP3 expression or inhibition of NLRP3 function (including NLRP3 activation).

[0065] In another preferred embodiment, the positive control includes: MCC950, CY-09, or a combination thereof.

[0066] In another preferred embodiment, the negative control substance includes: KCl.

[0067] In another preferred example, the test group includes (n-2) parallel test groups.

[0068] In another preferred embodiment, the method further comprises setting up a blank control group.

[0069] In another preferred embodiment, the co-incubation time is 0.5-3 hours, preferably 0.75-2 hours, and more preferably 1 hour.

[0070] In another preferred embodiment, the inducible expression condition is tetracycline or doxycycline induced expression, preferably doxycycline induced expression.

[0071] In another preferred embodiment, the concentration of doxycycline is 0.1-10 μg / ml, preferably 0.5-5 μg / ml, more preferably 1 μg / ml.

[0072] In another preferred embodiment, the time for inducing expression is 8-20 hours, preferably 10-15 hours, and more preferably 13 hours.

[0073] In another preferred embodiment, the detection includes lactate dehydrogenase (LDH) cytotoxicity detection and / or propidium iodide (PI) staining detection.

[0074] In another preferred embodiment, the cell death level includes the number of cell deaths and / or the ratio of cell death.

[0075] In another preferred embodiment, the step (d) comprises: calculating the number of cell deaths and / or the cell death ratio value V1 of the positive control group, the number of cell deaths and / or the cell death ratio value V0 of the negative control group, and the number of cell deaths and / or the cell death ratio value Vx of the test group;

[0076] If V1 < V0, it is determined that the test is valid; if V1 ≥ V0, it is determined that the test is invalid;

[0077] If Vx < V0, it is determined to be positive, that is, the candidate substance is an NLRP3 targeting inhibitor;

[0078] If Vx < V1, it is determined to be strongly positive, that is, the candidate substance is a highly efficient or potent NLRP3 targeting inhibitor;

[0079] If Vx ≥ V0, it is determined to be negative, that is, the candidate substance is not an NLRP3 targeting inhibitor.

[0080] In another preferred example, the method is also used to compare the efficiency of different candidate substances or drugs in targeting and inhibiting NLRP3 expression.

[0081] In another preferred example, the method is also used to compare the efficiency of different candidate substances or drugs in targeting and inhibiting NLRP3 activation.

[0082] In the fourth aspect of the present invention, a method for screening regulators involved in regulating NLRP3 inflammasome activation is provided, and the method includes the steps of:

[0083] (a) Co-transfecting a sgRNA library vector with a packaging plasmid and an envelope plasmid into packaging cells, and separating and / or purifying the obtained virus particles from the culture of the packaging cells;

[0084] (b) Infecting the genetically engineered cells as described in the second aspect of the present invention with the virus particles, and giving induction expression conditions;

[0085] (c) Screening according to the resistance gene and / or selective marker of the sgRNA library vector, and further screening out monoclonal cells that survive under induction expression conditions;

[0086] (d) Amplifying and extracting the monoclonal cells, and performing PCR amplification on the sgRNA; and

[0087] (e) By high-throughput sequencing and bioinformatics analysis, determining the sgRNAs with high abundance and determining the corresponding target genes, and the proteins expressed by the target genes are the regulators involved in regulating NLRP3 inflammasome activation.

[0088] In another preferred example, the method further includes the step of: determining the appropriate MOI value for virus particle infection.

[0089] In the fifth aspect of the present invention, a construction composition is provided, and the construction composition includes:

[0090] (Z1) an inducible viral vector, wherein the inducible viral vector comprises a coding sequence for a NLRP3 mutant protein;

[0091] (Z2) packaging plasmid; and

[0092] (Z3) Envelope protein particle.

[0093] In another preferred embodiment, the NLRP3 mutant protein is a NLRP3 gain-of-function mutant protein.

[0094] In another preferred embodiment, the inducible viral vector is a lentiviral vector.

[0095] In another preferred embodiment, the lentiviral vector is a Tet-On PLVX lentiviral vector.

[0096] In another preferred embodiment, the inducible viral vector is expressed by induction of doxycycline or tetracycline.

[0097] In another preferred embodiment, the packaging plasmid is a PXA2 plasmid.

[0098] In another preferred embodiment, the envelope protein plasmid is a VSVG plasmid.

[0099] In a sixth aspect of the present invention, a kit is provided, comprising: the genetically engineered cells as described in the second aspect of the present invention and instructions.

[0100] In another preferred embodiment, the kit further comprises a positive control, which is a NLRP3 targeted inhibitor; preferably a targeted inhibitor of NLRP3 mutant protein / gene, or a targeted inhibitor that inhibits NLRP3 function (including NLRP3 activation).

[0101] In another preferred embodiment, the positive control includes MCC950, CY-09, or a combination thereof.

[0102] In another preferred embodiment, the description records the method according to the third aspect of the present invention and / or the method according to the fourth aspect of the present invention.

[0103] In the seventh aspect of the present invention, there is provided a use of the genetically engineered cell according to the second aspect of the present invention, the constructed composition according to the fifth aspect of the present invention, and the kit according to the sixth aspect of the present invention, for:

[0104] (a) Induced expression of NLRP3 mutant protein;

[0105] (b) screening for NLRP3 targeted inhibitors; and / or

[0106] (c) Screening of regulatory factors involved in regulating NLRP3 inflammasome activation.

[0107] In another preferred embodiment, the NLRP3 mutant protein is a NLRP3 gain-of-function mutant protein.

[0108] In another preferred embodiment, the NLRP3 targeted inhibitor is used to treat cold and heat cycle associated syndrome (CAPS).

[0109] In another preferred embodiment, the hot and cold cycle associated syndrome (CAPS) includes: familial cold autoinflammatory syndrome (FCAS), Muckle-Wells syndrome (MWS) and chronic infantile neurocutaneous arthritis syndrome (CINCA).

[0110] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features specifically described below (such as embodiments) can be combined with each other to form a new or preferred technical solution. Due to space limitations, they will not be described one by one here. BRIEF DESCRIPTION OF THE DRAWINGS

[0111] Figure 1 The construction of NLRP3 knockout THP-1 cell line and functional verification are shown. (A) The genome of NLRP3 knockout and control THP-1 cell lines was extracted, and NLRP3 gene knockout was detected by sequencing after PCR. (BC) NLRP3 knockout and control THP1 cell lines were stimulated with Pam3CSK4 (1μg / ml) and PGN (2μg / ml) for 13h, and the supernatant and cells were collected at the same time. Caspase-1 and IL-1β cleavage were detected by WB, and IL-1β secretion level was detected by ELISA. (DE) NLRP3 knockout and control THP1 cells were resuspended in serum-free RPMI-1640 containing Hoechst 33342 and propidium iodide (PI), and doxycycline (1μg / ml) was treated for 13h. Images were collected using the Olympus FV-1200 laser confocal high-content analysis system, and representative images are shown in the figure. The proportion of cell death was analyzed using Image J software.

[0112] Figure 2 The K355T mutant induced stronger inflammasome activation in the 293T inflammasome reconstitution system. (A) SDS-PAGE and Western blot analysis of IL-1β cleavage. (B) ELISA detection of secreted IL-1β in the supernatant.

[0113] Figure 3 A map of pLVX-TetOne-NLRP3-BSD ligated with the human NLRP3 coding sequence is shown.

[0114] Figure 4 NLRP3 K353T mutant cells showed stronger inflammasome activation. (A) Wild-type and K353T mutant cells were treated with doxycycline (1μg / ml), and the supernatant and cells were collected at the same time after 13h. The proteins in the samples were concentrated, and WB was used to detect Capsase-1, GSDMD cleavage and NLRP3 expression. (B) Wild-type and K353T mutant cells were treated with doxycycline (1μg / ml) and LPS (1μg / ml) at the same time. The culture supernatant was collected after 13h, and ELISA was used to detect IL-1β secretion. (C) Wild-type and K355T mutant cells were treated with doxycycline (1μg / ml) for 13h, and the ASC oligomerization level was detected by WB. (DE) Wild-type and K353T mutant cells were resuspended in serum-free RPMI-1640 containing Hoechst 33342 and propidium iodide (PI). After 13 h of treatment with doxycycline (1 μg / ml), images were collected using an Olympus FV-1200 laser confocal high-content analysis system. Representative images are shown in the figure. The cell death rate was analyzed using Image J software. The scale bar is 100 μm. (F) Wild-type and K353T mutant cells were treated with doxycycline (1 μg / ml). After 13 h, the culture supernatant was collected and the level of cell death was detected using a lactate dehydrogenase (LDH) cytotoxicity detection kit.

[0115] Figure 5MCC950 inhibits NLRP3 inflammasome activation. (A) THP1 expressing NLRP3 K355T mutant was pretreated with MCC950 (10μM) or KCl (45mM) for 30min, and then treated with doxycycline (1μg / mL) for 13h. The supernatant and cells were collected at the same time, and related proteins were detected by WB. (B) THP1 expressing NLRP3 K355T mutant was pretreated with MCC950 (10μM) or KCl (45mM) for 30min, and then treated with doxycycline (1μg / mL) and LPS (1μg / mL) for 13h. The culture supernatant was collected, and ELISA was used to detect IL-1β secretion. (CD) K353T mutant cells were resuspended in serum-free RPMI-1640 containing Hoechst 33342 and propidium iodide (PI), and pretreated with MCC950 (10 μM) or KCl (45 mM) for 30 min. Then doxycycline (1 μg / mL) was added and the cells were treated for 13 h. Images were collected using an Olympus FV-1200 laser confocal high-content analysis system. Representative images are shown in the figure. The percentage of cell death was analyzed using Image J software. DETAILED DESCRIPTION

[0116] After extensive and in-depth research and a large number of screenings, the inventors unexpectedly discovered for the first time that constructing a THP-1 cell line that induces the expression of NLRP3 mutants (preferably CAPS mutation sites, such as K355T mutants) can effectively simulate the state of NLRP3-related diseases, especially the activation state of NLRP3 inflammasomes, and can therefore be used for: high-throughput screening of drugs targeting NLRP3 at the cellular level to treat inflammatory diseases, and screening of regulatory factors involved in regulating the activation of NLRP3 inflammasomes. In addition, NLRP3 carrying CAPS mutation sites can spontaneously activate inflammasomes and induce cell death, so it is often impossible to obtain a THP-1 cell line that stably expresses NLRP3 mutants. The design of induced expression is adopted in the present invention, so that the THP-1 cell line can stably express NLRP3 mutants and be used for the above-mentioned screening purposes. On this basis, the present invention was completed.

[0117] the term

[0118] In order that the present disclosure may be more readily understood, certain terms are first defined. As used in this application, unless otherwise expressly provided herein, each of the following terms shall have the meaning given below.

[0119] The term "about" can refer to a value or composition that is within an acceptable error range for the particular value or composition as determined by one of ordinary skill in the art, which will depend in part on how the value or composition is measured or determined.

[0120] As used herein, the term "NLRP3 mutant protein" is a gain-of-function protein, that is, the mutation type of the protein is a mutation type that results in the acquisition of a function that was not originally present. In the present invention, the function preferably refers to the state of presenting or simulating NLRP3-related diseases (inflammatory diseases), such as the state of cold and heat cycle associated syndrome (CAPS).

[0121] NLRP3 inflammasome

[0122] NLRP3 inflammasome (NOD-, LRR-and pyrin domain-containing 3inflammasome) is a multi-protein complex located in cells. After sensing a variety of pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs), the receptor protein NLRP3 of inflammasome activates the adaptor molecule ASC, promoting the assembly of ASC to form a helical fiber structure called speck. ASC then further recruits the effector molecule pro-caspase 1. The homologous caspase 1 dimer cleaves itself to produce activated mature caspase 1, and the activated caspase 1 further cleaves IL-1β precursor (pro-IL-1β) and pro-IL-18, which are then released together to the extracellular space through the non-classical secretion pathway. Activated caspase 1 can also cleave gasdermin D. The N-terminal protein of active gasdermin D is translocated to the cell membrane to form holes, eventually leading to cell pyroptosis and releasing a large number of danger signal molecules, activating more downstream chain reactions and causing tissue damage.

[0123] NLRP3 mainly consists of three functional domains, namely the PYRIN (PYD) domain at the N-terminus for recruiting the adaptor molecule ASC, multiple tandem leucine-rich (LRR) domains at the C-terminus, and the NACHT domain in the middle with ATP binding and hydrolase activity. The NACHT domain can be further subdivided into five domains, namely NBD, HD1, WHD, and HD2. The NLRP3 inflammasome can be activated by stimuli from many different sources and structures, including endogenous danger signals such as ATP, uric acid crystals, calcium phosphate crystals, and amyloid-β, and microbial-derived substances include a variety of bacterial toxins, bacteria, and viral RNA. Current studies suggest that NLRP3 can sense the intracellular homeostasis and dynamic changes in the cell membrane structure, thereby relieving the inhibitory state to achieve the purpose of responding to stimuli.

[0124] In the present invention, Pam3CSK4 or PGN is preferably selected as a stimulator of the NLRP3 inflammasome. Pam3CSK4 is a synthetic TLR2 receptor agonist, and PGN is a peptidoglycan on the surface of Gram-positive bacteria. Pam3CSK4 and PGN alone can activate the NLRP3 inflammasome in human monocytes, thereby simulating the state of NLRP3-related diseases (inflammatory diseases).

[0125] Hot and cold cycle syndrome

[0126] Cryopyrin-associated periodic syndrome (CAPS) is a rare autosomal dominant genetic disease, a general term for a class of autoinflammatory disorders caused by abnormal activation of the NLRP3 gene encoding mutations. CAPS is divided into three categories according to the severity of the disease, from mild to severe, familial cold autoinflammatory syndrome (FCAS), Muckle-Wells syndrome (MWS) and chronic infantile neurocutaneous arthritis syndrome (CINCA), among which CINCA is also known as neonatal multisystem inflammatory syndrome (NOMID).

[0127] So far, more than 200 NLRP3-related mutations have been identified in CAPS patients. These mutations lead to overactivation of the NLRP3 gene, thereby inducing the body to produce a large number of pro-inflammatory cells due to IL-1β, leading to inflammatory symptoms such as intermittent attacks of rash, fever, joint pain, and in severe cases, progressive deafness, renal amyloidosis and central nervous system diseases, such as aseptic encephalitis and brain atrophy. These mutations are summarized in the INFEVER database. CAPS mutations mostly occur in the NLRP3NACHT domain. It is speculated that mutations in the NACHT domain may affect the normal folding of the NLRP3 protein, thereby causing abnormal activation. Among them, A352 and L353 are MWS and FCAS-related mutations that were identified very early, and NLRP3 + / A350V and NLRP3 + / L351P Knock-in mice also mimicked the characteristics of patients, showing strong inflammation.

[0128] The inventors unexpectedly discovered for the first time that K355 (i.e., lysine 355 based on the amino acid sequence of the NLRP3 protein as shown in SEQ ID NO: 1) near the A350 and L351 sites, K355T is an activation-enhanced mutant associated with Muckle-Wells syndrome (MWS) patients, and is an MWS-related activation-enhanced mutation site. Therefore, the inventors' research on constructing cell lines, screening drugs, and regulating factors mainly revolved around this site.

[0129] Tet controllable gene expression system

[0130] The regulatory mechanism of the tet operon is achieved through the tet repressor (tetR). The tetR protein binds to the DNA called the tetracycline / doxycycline (doxycycline is a derivative of tetracycline) operator sequence (tet operator, tetO) to exert transcriptional repression. Tetracycline / doxycycline prevents tetR from binding to tetO, thereby reversing the transcriptional repression caused by tetR. By fusing the DNA binding domain sequence of the tetR gene with the gene expression activation domain sequence of herpes simplex virus VP16, a tetracycline / doxycycline-controlled transcriptional activator protein (tettranscriptional activator, tTA) can be expressed. tTA needs to bind to a suitable Tet-responsive promoter to function.

[0131] The Tet response promoter can be some strings of tetO repeat sequences (tet response element, TRE). The TRE promoter is the promoter of the second-generation Tet-On system, which is placed upstream of the minimal promoter of cytomegalovirus (CMV) so as to be properly aligned with the activation domain of VP16 so that the binding of tTA can activate transcription; the Tet response promoter can also be the TRE3G promoter. The TRE3G promoter is the promoter of the third-generation Tet-On system. Compared with the second-generation Tet promoter, the TRE3G promoter has a lower degree of leakage inducing expression and a lower background activity.

[0132] The Tet-controllable gene expression regulation system is divided into Tet-Off and Tet-On.

[0133] Tet-Off system: In the absence of tetracycline / doxycycline, tTA protein continues to act on the Tet promoter, allowing the gene to be continuously expressed. This system is very useful when the transgene needs to be maintained in a state of continuous expression. When tetracycline / doxycycline is added, tetracycline / doxycycline can bind to tTA and change the structure of tTA protein, making it unable to bind to the promoter, thereby reducing the expression level of the gene it drives. In order to keep the system in the "off" state, tetracycline / doxycycline must be added continuously.

[0134] Tet-On system: When studying mutant tTA genes, it was found that some mutants (recombinant tTA, rtTA) no longer bind to the Tet promoter; only in the presence of tetracycline / doxycycline can rtTA bind to the Tet promoter sequence to activate the gene and express it. Since the gene is expressed only when tetracycline / doxycycline is added, it is called the Tet-On system. When using this system, the transgene is not expressed in the absence of tetracycline / doxycycline. Only when tetracycline / doxycycline is added will rtTA be allowed to bind to the Tet promoter to induce transcription.

[0135] Construction method

[0136] The present invention provides a method for constructing a genetically engineered cell that can induce expression of a NLRP3 mutant protein.

[0137] In the art, NLRP3 carrying CAPS mutation sites can spontaneously activate inflammasomes and induce cell death, so it is often difficult to obtain THP-1 cell lines that stably express NLRP3 mutants. However, the construction method of the present invention adopts an induced expression design, so that the genetically engineered cells (such as THP-1 cell lines) obtained by construction can stably express NLRP3 mutant proteins, and thus can be used for a variety of high-throughput screening purposes.

[0138] Genetically engineered cells

[0139] The genetically engineered cells (such as THP-1 cell line and BLaER1 cell line) obtained by the construction method of the present invention can stably express NLRP3 mutant protein, and the expression mode is induced expression (doxycycline induced expression).

[0140] Typically, the mutation type of the NLRP3 mutant protein is a mutation in a CAPS patient mutant. For example, based on the amino acid sequence of the wild-type NLRP3 protein, there are one or more mutations, and the mutation site is selected from the following group: position 350, position 351, position 352, position 353, position 354, position 355, or a combination thereof; wherein the amino acid sequence of the wild-type NLRP3 protein is shown in SEQ ID NO: 1.

[0141] Preferably, the present invention relates to an NLRP3 protein with a K355T mutation, that is, an NLRP3 K355T protein, having an amino acid sequence as shown in SEQ ID NO: 2. The inventors have experimentally verified that NLRP3K355T is an activation-enhanced mutant, and the activated NLRP3 K355T is structurally more unstable, so its protein level is lower than WT. The addition of the inhibitor MCC950 (an inhibitor of NLRP3 activation) can stabilize the NLRP3 K355T protein and increase the amount of NLRP3 protein.

[0142] Screening methods

[0143] In the present invention, various screening uses of genetically engineered cells are provided.

[0144] For example, a method for screening NLRP3 targeted inhibitors is provided, the method comprising the steps of:

[0145] (a) providing a genetically engineered cell according to the second aspect of the present invention, and dividing the genetically engineered cell into n portions, where n is a positive integer ≥ 3 (e.g., 3-10 portions, for example, 3, 4, 5, or 6 portions);

[0146] (b) setting up a negative control group, a positive control group and a test group, and providing conditions for inducing expression;

[0147] The test conditions of the negative control group, the positive control group and the test group are the same, except that:

[0148] In the negative control group, at least one of the genetically engineered cells is co-incubated with a negative control substance;

[0149] In the positive control group, at least one of the genetically engineered cells is co-incubated with a positive control;

[0150] In the test group, at least one of the genetically engineered cells is co-incubated with a candidate substance;

[0151] (c) detecting the cell death levels of the negative control group, the positive control group and the test group; and

[0152] (d) comparing the cell death levels of the negative control group, the positive control group and the test group to determine whether the candidate substance is a NLRP3 targeted inhibitor, and / or determining the efficiency of the candidate substance in targeted inhibition of NLRP3 expression or inhibition of NLRP3 function (including NLRP3 activation).

[0153] The above NLRP3 targeted inhibitors may be inhibitors that inhibit NLRP3 expression, or inhibitors that inhibit NLRP3 function / activity (including activation).

[0154] The positive control includes: MCC950, CY-09, or a combination thereof; wherein MCC950 is an inhibitor that inhibits the ATPase activity of NLRP3 by directly binding thereto, thereby achieving the purpose of inhibiting its function.

[0155] The negative control is preferably KCl.

[0156] The determination of the screening result is as follows:

[0157] Step (d) includes: calculating the number of dead cells and / or the proportion value V1 of dead cells in the positive control group, the number of dead cells and / or the proportion value V0 of dead cells in the negative control group, and the number of dead cells and / or the proportion value Vx of dead cells in the test group;

[0158] If V1 < V0, it is determined that the test is valid; if V1 ≥ V0, it is determined that the test is invalid;

[0159] If Vx < V0, it is determined as positive, that is, the candidate substance is an NLRP3-targeted inhibitor;

[0160] If Vx < V1, it is determined as strongly positive, that is, the candidate substance is a highly effective or potent NLRP3-targeted inhibitor;

[0161] If Vx ≥ V0, it is determined as negative, that is, the candidate substance is not an NLRP3-targeted inhibitor.

[0162] The above screening method based on cell death calculation can be used not only for qualitative judgment but also for quantitative judgment, and thus can also compare the efficiency of different candidate substances or drugs in targeting and inhibiting NLRP3 expression or the efficiency of targeting and inhibiting NLRP3 activation.

[0163] In the present invention, a method for screening regulators involved in regulating NLRP3 inflammasome activation is also provided. The method includes the steps:

[0164] (a) Co-transfecting a sgRNA library vector with a packaging plasmid and an envelope plasmid into packaging cells, and isolating and / or purifying the obtained virus particles from the culture of the packaging cells;

[0165] (b) Infecting the genetically engineered cells as described in the second aspect of the present invention with the virus particles and giving induction expression conditions;

[0166] (c) Screening according to the resistance gene and / or selective marker of the sgRNA library vector, and further screening out monoclonal cells surviving under the induction expression conditions;

[0167] (d) Amplifying and extracting the monoclonal cells, and performing PCR amplification on the sgRNA; and

[0168] (e) Through high-throughput sequencing and bioinformatics analysis, the high-abundance sgRNA and the corresponding target gene are determined, and the protein expressed by the target gene is the regulatory factor involved in regulating the activation of NLRP3 inflammasome.

[0169] Main advantages of the present invention

[0170] Through the construction method of the present invention, genetically engineered cells (such as THP-1 cell lines) expressing NLRP3 mutants of CAPS patients can be constructed, and this cell line can be used to further screen small drug molecules for treating CAPS patients and regulatory factors that regulate NLRP3 activation. Screening using the genetically engineered cells of the present invention has the following advantages:

[0171] 1. It is not necessary to collect samples such as peripheral blood from CAPS patients, and the source of experimental materials is more convenient;

[0172] 2. The cell line is stably maintained and can support high-throughput screening;

[0173] 3. Whether the function is being performed can be judged by observing the cell death, and the observation indicators are simple and easy to judge.

[0174] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are intended to illustrate the present invention only and are not intended to limit the scope of the present invention. The experimental methods in the following examples where specific conditions are not specified are usually performed under conventional conditions, such as those described in Sambrook et al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989), or under conditions recommended by the manufacturer. Unless otherwise indicated, percentages and parts are weight percentages and weight parts.

[0175] Example 1 Construction of THP-1 cell line expressing NLRP3 K355T mutant

[0176] 1. Construction of NLRP3 gene knockout THP-1 cell line and functional verification:

[0177] The CRISPR / Cas9 system was used to construct a knockout cell line. First, the sgRNA targeting the human NLRP3 gene (whose coding sequence is CACCGGAAGAAGACGTACACCGCGG, recorded as SEQ ID NO: 4) was synthesized and connected to the Lenti-Crispr V2 (Addgene) lentiviral vector. HEK293T cells were used for lentiviral packaging, and the auxiliary packaging plasmids included PXA2 and VSVG. The mass ratio of the transfected plasmids was lenti-crispr-sgRNA: PXA2: VSVG = 10:7.5:5.

[0178] 48 hours after transfection, the culture supernatant of 293T cells was collected, filtered through a 0.45μm filter membrane, and infected with wild-type THP-1 cells (0.3 million cells / well) that had been pre-plated in a 6-well plate. After 24 hours of infection, the culture medium was replaced with fresh RPMI-1640. 24 hours after the medium change, the cells were transferred to a T25 Flask culture flask and 2μg / ml puromycin was added for selection for 3 days. The cells that survived the antibiotic selection were subjected to limiting dilution, and the final cell density reached 5 cells / ml suspension. 96-well cell culture plates were plated for monoclonal cell culture. After 20 days, an appropriate amount of cells (about 1*10 5 Cells), extract the cell genome, perform PCR sequencing and Western blot to identify the protein knockout efficiency.

[0179] like Figure 1 As shown in A, the genomes of NLRP3 knockout and control THP-1 cell lines were extracted, and PCR followed by sequencing to detect the knockout of the NLRP3 gene.

[0180] NLRP3 knockout and control THP1 cell lines were stimulated with Pam3CSK4 (1 μg / ml) and PGN (2 μg / ml) for 13 h, and the supernatant and cells were collected. Caspase-1 and IL-1β cleavage were detected by WB, and IL-1β secretion level was detected by ELISA.

[0181] like Figure 1 As shown in B, it is shown that Pam3CSK4 or PGN-induced caspase-1 cleavage in NLRP3 knockout THP-1 cells was significantly inhibited compared with the control group.

[0182] like Figure 1 As shown in C, IL-1β secretion induced by Pam3CSK4 or PGN in NLRP3 knockout THP-1 cells was significantly inhibited compared with the control group.

[0183] Furthermore, NLRP3 knockout and control THP1 cells were resuspended in serum-free RPMI-1640 containing Hoechst 33342 and propidium iodide (PI) and treated with doxycycline (1 μg / ml) for 13 h. Images were collected using the Olympus FV-1200 laser confocal high-content analysis system, and the cell death ratio was analyzed using Image J software.

[0184] like Figure 1 In D, representative images are shown.

[0185] like Figure 1 FIG. 5E shows that Pam3CSK4- or PGN-induced cell death in NLRP3-knockout THP-1 cells was significantly inhibited compared with the control group.

[0186] 2. Complementation of NLRP3 wild-type and K355T mutant in NLRP3 knockout THP-1 cell line:

[0187] (1) Construction of K355T mutant:

[0188] The NLRP3 K355T mutant was constructed by point mutation. Lysine (K) at position 355 was mutated to threonine (T) on the PCR primer, and mutation PCR was performed using KOD-PLUS DNA polymerase (TOYOBO). The PCR product was digested with DPNI and transformed into Escherichia coli DH5a, and the plasmid was extracted and sequenced for verification.

[0189] (2) Preliminary verification of K355T function using the 293T recombination system:

[0190] According to 1×10 per well 5 HEK293T cells were plated into 96-well plates one day in advance. The cell medium was replaced with opti-MEM before transfection. The plasmids expressing the inflammasome recombinant system were transfected using Lipo2000 transfection reagent (Thermo Fisher Scientific), which were pcDNA4.0-ASC (2.5 ng), Fugw-pro-caspase 1 (2.5 ng), pcDNA4.0-pro-IL-1β (25 ng), pcDNA3.1-flag NLRP3 (20 ng) wild type or NLRP3 mutant.

[0191] 24 hours after transfection, the cell supernatant was collected and the secreted IL-1β in the supernatant was detected by ELISA. Alternatively, the cells were directly lysed in the culture wells with 5×SDS-loading buffer, and the samples were boiled at 95°C and used for SDS-PAGE and Western blot analysis of IL-1β cleavage.

[0192] like Figure 2 As shown in A, it is shown that K355T can induce more IL-1β cleavage compared with the wild type.

[0193] at the same time Figure 2 A also shows that the expression level of NLRP3 in the K355T mutant is significantly lower than that in the WT. There are two reasons for this: 1. The number of inserted copies of WT and K355T is different when the cell lines are complemented by lentiviral infection; 2. The K355T mutant protein is more unstable in structure. Figure 5As shown in A, after adding the inhibitor MCC950 to stabilize the NLRP3 K355T protein, the amount of NLRP3 protein will increase. NLRP3K355T is an activation-enhanced mutant. The inventors speculate that because the activated NLRP3K355T is more unstable in structure, its protein level is lower than that of WT.

[0194] like Figure 2 As shown in B, it is shown that K355T can induce more IL-1β secretion compared with the wild type.

[0195] (3) Construction of doxycycline-induced NLRP3 expression THP-1 cell line by lentiviral complementation:

[0196] NLRP3 carrying the CAPS mutation site can spontaneously activate inflammasomes and induce cell death, so it is impossible to obtain a THP-1 cell line that stably expresses NLRP3. Therefore, the inventors used a doxycycline inducible expression system.

[0197] First, the coding sequences of human NLRP3 wild type and K355T mutant were ligated into Tet-On PLVX lentiviral vector (Figure 2 Figure 3 As shown), 293T cells were co-transfected with PXA2 and VSVG auxiliary packaging plasmids. 293T cell culture supernatant was collected 48 hours after transfection, filtered through a 0.45μm filter membrane, and infected with NLRP3 knockout THP1 cells. 5μg / ml blasticidin was used for screening for one week, and then 1μg / ml doxycycline was added to induce NLRP3 expression by limiting dilution, and the induced expression efficiency was identified by Western blot.

[0198] (4) Verification of the function of the NLRP3 K355T mutant in the THP-1 cell line:

[0199] Wild-type and K353T mutant cells were treated with doxycycline (1 μg / ml). After 13 h, the supernatant and cells were collected at the same time. The proteins in the samples were concentrated, and Capsase-1, GSDMD cleavage and NLRP3 expression were detected by WB.

[0200] like Figure 4 As shown in A, the results show that when treated with doxycycline, THP-1 cells complemented with K355T NLRP3 exhibited stronger Capsase-1 and GSDMD cleavage than THP-1 cells complemented with wild-type NLRP3.

[0201] Wild-type and K353T mutant cells were treated with doxycycline (1 μg / ml) and LPS (1 μg / mL) at the same time. The culture supernatant was collected after 13 h and IL-1β secretion was detected by ELISA.

[0202] like Figure 4 As shown in B, the results show that when treated with doxycycline, THP-1 cells complemented with K355T NLRP3 exhibited a stronger IL-1β release compared with THP-1 cells complemented with wild-type NLRP3.

[0203] Wild-type and K355T mutant cells were treated with doxycycline (1 μg / ml) for 13 h, and the ASC oligomerization level was detected by WB.

[0204] like Figure 4 As shown in C, the results show that when treated with doxycycline, THP-1 cells complemented with K355T NLRP3 have more ASC oligomers, ASC dimers, and ASC monomers compared to THP-1 cells complemented with wild-type NLRP3.

[0205] Wild-type and K353T mutant cells were resuspended in serum-free RPMI-1640 containing Hoechst 33342 and propidium iodide (PI). After being treated with doxycycline (1 μg / ml) for 13 h, images were collected using an Olympus FV-1200 laser confocal high-content analysis system, and the cell death ratio was analyzed using Image J software. Scale bar: 100 μm.

[0206] like Figure 4 In D, representative images are shown.

[0207] like Figure 4 As shown in E, the results show that when treated with doxycycline, THP-1 cells complemented with K355T NLRP3 exhibited more cell death compared to THP-1 cells complemented with wild-type NLRP3.

[0208] Wild-type and K353T mutant cells were treated with doxycycline (1 μg / ml), and the culture supernatant was collected 13 h later. The lactate dehydrogenase (LDH) cytotoxicity detection kit was used to detect the level of cell death.

[0209] like Figure 4 As shown in F, the results show that when treated with doxycycline, THP-1 cells complemented with K355T NLRP3 exhibited more cell death compared with THP-1 cells complemented with wild-type NLRP3.

[0210] These results indicate that when treated with doxycycline, THP-1 cells supplemented with K355T NLRP3 exhibited stronger inflammasome activation than THP-1 cells supplemented with wild-type NLRP3.

[0211] Example 2 Application of NLRP3 gene knockout THP-1 line complemented with K355T NLRP3

[0212] 1. High-throughput screening of drugs targeting NLRP3 for the treatment of inflammatory diseases:

[0213] (1) Determine the lowest dose and shortest induction time of doxycycline that causes complete cell death:

[0214] The NLRP3 knockout THP-1 cells complemented with K355T NLRP3 were resuspended in RPMI-1640 medium and plated at 2×10 5 The cells were plated in a 96-well plate at a density of 100 μg / ml. Different concentrations of doxycycline were added for 30 min to induce expression for different time periods, namely 2 h, 4 h, 8 h, and 12 h, and cell death was detected to find the doxycycline concentration with the lowest dose and the shortest induction time that can cause all cells to die.

[0215] (2) Screening for drugs that inhibit NLRP3 activation:

[0216] The screening method is as follows: NLRP3 knockout THP-1 cells complemented with K355T NLRP3 were resuspended in serum-free RPMI-1640 medium containing Propidium Iodide (2.5 μg / ml) and 2×10 5 The cells were plated in a 96-well plate at a density of 10 μM. After 30 minutes, different drugs to be tested, positive control MCC950 (10 μM), negative control KCl (45 mM) and DMSO blank control (most small molecule inhibitors use DMSO as a solvent, and DMSO has certain cytotoxicity, so DMSO needs to be used as a blank control) were added for pretreatment for 1 hour. 1 μg / ml doxycycline was added to induce the expression of NLRP3. After 13 hours, the cell supernatant was collected and the lactate dehydrogenase cytotoxicity detection kit (Promega) was used to detect the level of cell death. The specific operation of the lactate dehydrogenase (LDH) cytotoxicity detection kit is as follows:

[0217] Add LDH detection working solution, place at room temperature for 20 minutes, and read the fluorescence value (excitation light 560nm, emission light 590nm, gain 55). One of the wells was added with cell lysis solution 4 hours in advance. This well is the maximum lysis well and is set as the positive control. Another well is added with culture medium only. This well is the background signal. The ratio of LDH release is calculated by the following formula: LDH Release (%) = 100 × (sample value - culture medium background value) / (positive control - culture medium background value).

[0218] Propidium iodide (PI) staining was used to detect cell death. Propidium iodide (PI) can penetrate the cell membrane of dead cells and release red fluorescence after embedding into double-stranded DNA. The level of cell death was identified by counting the proportion of red cells to total cells. THP1 cells were resuspended in serum-free RPMI-1640 medium supplemented with Propidium Iodide (2.5 μg / ml). 5×10 cells were added to each well. 4 After inducing inflammasome activation, the propidium iodide (PI) signal was detected using an ELISA reader (excitation light 535 nm, emission light 617 nm).

[0219] Taking the positive control MCC950 as an example, the inventors verified that MCC950 inhibited NLRP3 inflammasome activation as follows:

[0220] THP1 cells expressing NLRP3 K355T mutant were pretreated with MCC950 (10 μM) or KCl (45 mM) for 30 min, and then treated with doxycycline (1 μg / mL) for 13 h. The supernatant and cells were collected at the same time, and related proteins were detected by WB.

[0221] like Figure 5 As shown in A, the results showed that the NLRP3-specific inhibitor MCC950 could significantly inhibit the activation of the K355T mutant, the cleavage of Caspase-1 and gasdermin D.

[0222] MCC950 is reported to inhibit NLRP3 function by directly binding to it and inhibiting its ATPase activity. As mentioned above, the structure of K355T NLRP3 is unstable when it is activated. MCC950 can stabilize the conformation of the mutant after binding to it. Therefore, compared with the DMSO group, the NLRP3 protein in the MCC950 pretreatment group is higher, indicating that MCC950 can significantly inhibit the activation of the K355T NLRP3 mutant.

[0223] THP1 cells expressing NLRP3 K355T mutant were pretreated with MCC950 (10 μM) or KCl (45 mM) for 30 min, and then treated with doxycycline (1 μg / mL) and LPS (1 μg / mL) for 13 h. The culture supernatant was collected and IL-1β secretion was detected by ELISA.

[0224] like Figure 5 As shown in B, the results showed that the NLRP3-specific inhibitor MCC950 could significantly inhibit IL-1β secretion.

[0225] K353T mutant cells were resuspended in serum-free RPMI-1640 containing Hoechst 33342 and propidium iodide (PI), and pretreated with MCC950 (10μM) or KCl (45mM) for 30min. Then doxycycline (1μg / mL) was added and the cells were treated for 13h. Images were collected using an Olympus FV-1200 laser confocal high-content analysis system. Representative images are shown in the figure, and the proportion of cell death was analyzed using Image J software.

[0226] like Figure 5 As shown in C and 5D, the results showed that the NLRP3-specific inhibitor MCC950 significantly reduced cell death.

[0227] Moreover, according to the comparison results of the KCl group, it was shown that the extracellular addition of potassium ions could not significantly inhibit the activation of the K355T mutant.

[0228] The above verification showed that the positive control system was successfully established. Therefore, this cell line can be used to screen a large number of drugs that may affect NLRP3 K355T activation by detecting cell death indicators. Candidate substances that can inhibit NLRP3 K355T activation have the potential to be developed as drugs for the prevention and / or treatment of CAPS.

[0229] Drugs for the prevention and / or treatment of CAPS can be screened using the following criteria:

[0230] If the cell death in the positive control group is less than that in the negative control group, the test is considered valid; if the cell death in the positive control group is greater than or equal to that in the negative control group, the test is considered invalid;

[0231] If the cell death in the test group is less than that in the negative control group, it is judged as positive, that is, the candidate substance is a NLRP3 targeted inhibitor;

[0232] If the cell death in the test group is less than that in the positive control group, it is judged as a strong positive, that is, the candidate substance is a highly effective or potent NLRP3 targeted inhibitor;

[0233] If the cell death in the test group is ≥ that in the negative control group, it is judged as negative, that is, the candidate substance is not a NLRP3 targeted inhibitor.

[0234] 2. Screening of regulatory factors involved in regulating NLRP3 inflammasome activation:

[0235] (1) Transfer the sgRNA library into the NLRP3 gene knockout THP-1 cell line complemented with K355T NLRP3 as described above:

[0236] Determination of the optimal MOI:

[0237] The sgRNA library was co-transfected with the auxiliary packaging plasmids PXA2 and VSVG into HEK293T for lentiviral packaging. 48 hours after transfection, the 293T cell culture supernatant containing lentiviral particles was collected and filtered through a 0.45μm filter membrane to infect the NLRP3 gene knockout THP-1 cells that had been pre-plated in a 6-well plate with K355T NLRP3 complemented. Then, the viral particles with different dilution gradients were diluted in a 6-well plate using the serial dilution method and cultured for 72 hours. Determine the MOI range:

[0238] a. Lentivirus with fluorescent label: 72 hours after infection, observe the cell status and fluorescence under a fluorescence microscope to make sure that the cells are in good condition and the fluorescence is less than 30%, preferably in 10%-20% of the wells, to ensure that each cell is transferred with at most one sgRNA, corresponding to a more appropriate MOI value.

[0239] b. Lentivirus without fluorescent label: Determine the optimal MOI value through resistance screening. Add appropriate antibiotics 72 hours after lentivirus infection, culture for 3-5 days, observe under a microscope, and select the wells with higher cell survival rate and better cell status, which correspond to the more appropriate MOI value.

[0240] MOI = virus amount / cell amount.

[0241] (2) Screening regulatory factors using sgRNA libraries:

[0242] Take the virus (optimal MOI value) to infect the NLRP3 gene knockout THP-1 cell line complemented with K355T NLRP3 that has been pre-plated in a 6-well plate. Add 1ml of virus suspension to each well. The virus suspension is diluted in complete medium with a final concentration of 5-8μg / mL of polybrene. Gently mix the virus and medium by inversion, do not vortex to mix. Remove the old medium, add 1ml of diluted virus suspension to each well to infect the cells, and then add 1ml of complete medium containing polybrene. Incubate the culture plate at 5% CO2 and 37℃ for 48h and then replace the medium. After 48h, add the concentration of doxycycline that can cause the lowest dose and shortest induction time of all cell death to the cells. Using eGFP control, fluorescent cells can be counted using a cell counter or fluorescence microscope.

[0243] To select stably transduced cells, replace the old medium with fresh complete medium containing doxycycline every 3-4 days until resistant cell colonies are visible (usually 7-14 days after screening). After selecting successfully transduced cells, replace them with normal complete medium and culture for 2-7 days. Then screen for cell clones that have not died after adding doxycycline.

[0244] To achieve 400-fold coverage of the sgRNA library, at least 3 × 10 7 Cells were used for genomic DNA extraction, and then sgRNA was amplified by PCR. High-Fidelity 2XPCR Master Mix (New England Biolabs). Then, the <300bp PCR product was isolated from the agarose gel and high-throughput amplicon sequencing was performed. The sgRNA read counts were analyzed by MAGeCK v0.5.7 software, and several high-abundance sgRNAs were identified by RIGER analysis to determine the target gene. The protein expressed by the above target gene is the regulatory factor involved in regulating the activation of the NLRP3 inflammasome.

[0245] All documents mentioned in the present invention are cited as references in this application, just as each document is cited as reference individually. In addition, it should be understood that after reading the above teachings of the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms also fall within the scope defined by the claims attached to this application.

[0246] Sequence Listing

[0247] SEQ ID NO: 1 (amino acid sequence of wild-type NLRP3 protein)

[0248] >human NLRP3 protein sequence WT

[0249] MASTRCKLARYLEDLEDVDLKKFKMHLEDYPPQKGCIPLPRGQTEKADHVDLATLMIDFNGEEKAWAMAVWIFAAINRRDLYEKAKRDEPKWGSDNARVSNPTVICQEDSIEEEWMGLLEYLSRISICKMKKDYRKKYRKYVRSRFQCIEDRNARLGESVSLNKRYTRLRLIKEHRSQQEREQELLAIGKTKTCESPVSPIKMELLFDPDDEHSEPVHTVVFQGAAGIGKTILARKMMLDWASGTLYQDRFDYLFYIHCREVSLVTQRSLGDLIMSCCPDPNPPIHKIVRKPSRILFLMDGFDELQGAFDEHIGPLCTDWQKAERGDILLSSLIRKKLLPEASLLITTRPVALE KLQHLLDHPRHVEILGFSEAKRKEYFFKYFSDEAQARAAFSLIQENEVLFTMCFIPLVCWIVCTGLKQQMESGKSLAQTSKTTTAVYVFFLSSLLQPRGGSQEHGLCAHLWGLCSLAADGIWNQKILFEESDLRNHGLQKADVSAFLRMNLFQKEVDCEKFYSFIHMTFQEFFAAMYYLLEEEKEGRTNVPGSRLKLPSRDVTVLLENYGKFEKGYLIFVVRFLFGLVNQERTSYLEKKLSCKISQQIRLELLKWIEVKAKAKKLQIQPSQLELFYCLYEMQEEDFVQRAMDYFPKIEINLSTRMDHMVSSFCIENCHRVESLSLGFLHNMPKEEEEEEKEGRHLDMVQCVLPSSSHAACSHGLVNSHLTSSFCRGLFSVLSTSQSLTELDLSDNSLGDPGMRVLCETLQHPGCNIRRLWLGRCGLSHECCFDISLVLSSNQKLVELDLSDNALGDFGIRLLCVGLKHLLCNLKKLWLVSCCLTSACCQDLASVLSTSHSLTRLYVGENALGDSGVAILCEKAKNPQCNLQKLGLVNSGLTSVCCSALSSVLSTNQNLTHLYLRGNTLGDKGIKLLCEGLLHPDCKLQVLELDNCNLTSHCCWDLSTLLTSSQSLRKLSLGNNDLGDLGVMMFCEVLKQQSCLLQNLGLSEMYFNYETKSALETLQEEKPELTVVFEPSW*

[0250] SEQ ID NO:2 (Amino acid sequence of NLRP3 protein with K355T mutation)

[0251] >human NLRP3 protein sequence K355T

[0252] MASTERCKLARYLEDLEDVDLKKFKMHLEDYPPQKGCIPLPRGQTEKADHVDLATLMIDFNGEEKAWAMAVWIFAAINRRDLYEKAKRDEPKWGSDNARVSNPTVICQEDSIEEEWMGLLEYLSRISICKMKKDYRKKYRKYVRSRFQCIEDRNARLGESVSLNKRYTRLRLIKEHRSQQEREQELLAIGKTKTCESPVSPIKMELLFDPDDEHSEPVHTVVFQGAAGIGKTILARKMMLDWASGTLYQDRFDYLFYIHCREVSLVTQRSLGDLIMSCCPDPNPPIHKIVRKPSRILFLMDGFDELQGAFDEHIGPLCTDWQKAERGDILLSSLIRKKLLPEASLLITTRPVALE TLQHLLDHPRHVEILGFSEAKRKEYFFKYFSDEAQARAAFSLIQENEVLFTMCFIPLVCWIVCTGLKQQMESGKSLAQTSKTTTAVYVFFLSSLLQPRGGSQEHGLCAHLWGLCSLAADGIWNQKILFEESDLRNHGLQKADVSAFLRMNLFQKEVDCEKFYSFIHMTFQEFFAAMYYLLEEEKEGRTNVPGSRLKLPSRDVTVLLENYGKFEKGYLIFVVRFLFGLVNQERTSYLEKKLSCKISQQIRLELLKWIEVKAKAKKLQIQPSQLELFYCLYEMQEEDFVQRAMDYFPKIEINLSTRMDHMVSSFCIENCHRVESLSLGFLHNMPKEEEEEEKEGRHLDMVQCVLPSSSHAACSHGLVNSHLTSSFCRGLFSVLSTSQSLTELDLSDNSLGDPGMRVLCETLQHPGCNIRRLWLGRCGLSHECCFDISLVLSSNQKLVELDLSDNALGDFGIRLLCVGLKHLLCNLKKLWLVSCCLTSACCQDLASVLSTSHSLTRLYVGENALGDSGVAILCEKAKNPQCNLQKLGLVNSGLTSVCCSALSSVLSTNQNLTHLYLRGNTLGDKGIKLLCEGLLHPDCKLQVLELDNCNLTSHCCWDLSTLLTSSQSLRKLSLGNNDLGDLGVMMFCEVLKQQSCLLQNLGLSEMYFNYETKSALETLQEEKPELTVVFEPSW*

[0253] SEQ ID NO:3 (Coding sequence of NLRP3 protein with K355T mutation)

[0254] >human NLRP3 gene sequence K355T

[0255]

[0256] SEQ ID NO:4 (sgRNA coding sequence)

[0257] CACCGGAAGAAGACGTACACCGCGG

Claims

1. A method for constructing a genetically engineered cell that can induce expression of a NLRP3 mutant protein, characterized in that: The method comprises the steps of: (i) providing an inducible viral vector and transfecting packaging cells, wherein the inducible viral vector comprises a coding sequence for a NLRP3 mutant protein; (ii) isolating and / or purifying the obtained viral particles from the culture of the packaging cells; and (iii) using the viral particles to infect host cells, thereby obtaining the genetically engineered cells, wherein the endogenous NLRP3 gene of the host cells is knocked out; Furthermore, the NLRP3 mutant protein is a NLRP3 gain-of-function mutant protein.

2. The method according to claim 1, characterized in that When the inducible viral vector is a lentiviral vector, the step (i) comprises a sub-step (ia): co-transfecting the packaging cell with the inducible viral vector, a packaging plasmid and an envelope protein plasmid.

3. A genetically engineered cell, characterized in that: The genetically engineered cells are induced to express NLRP3 mutant protein.

4. The genetically engineered cell according to claim 3, characterized in that The NLRP3 mutant protein has a K355T mutation based on the amino acid sequence of the wild-type NLRP3 protein.

5. A method for screening NLRP3 targeted inhibitors, characterized in that: The method comprises the steps of: (a) providing the genetically engineered cell as claimed in claim 3, and dividing it into n portions, where n is a positive integer ≥ 3 (e.g., 3-10 portions, for example, 3, 4, 5, or 6 portions); (b) setting up a negative control group, a positive control group and a test group, and providing conditions for inducing expression; The test conditions of the negative control group, the positive control group and the test group are the same, except that: In the negative control group, at least one of the genetically engineered cells is co-incubated with a negative control substance; In the positive control group, at least one of the genetically engineered cells is co-incubated with a positive control; In the test group, at least one of the genetically engineered cells is co-incubated with a candidate substance; (c) detecting the cell death levels of the negative control group, the positive control group and the test group; and (d) comparing the cell death levels of the negative control group, the positive control group and the test group to determine whether the candidate substance is a NLRP3 targeted inhibitor, and / or determining the efficiency of the candidate substance in targeted inhibition of NLRP3 expression or inhibition of NLRP3 function (including NLRP3 activation).

6. The method according to claim 5, characterized in that The method is also used to compare the efficiency of different candidate substances or drugs in targeting and inhibiting NLRP3 expression.

7. A method for screening regulatory factors involved in regulating NLRP3 inflammasome activation, characterized in that: The method comprises the steps of: (a) co-transfecting the sgRNA library vector with the packaging plasmid and the envelope protein plasmid into packaging cells, and isolating and / or purifying the obtained viral particles from the culture of the packaging cells; (b) using the virus particles to infect the genetically engineered cells according to claim 3, and providing inducing expression conditions; (c) screening according to the resistance gene and / or selectable marker of the sgRNA library vector, and further screening out monoclonal cells that survive under the induced expression conditions; (d) amplifying and extracting the monoclonal cells, and performing PCR amplification on the sgRNA; and (e) Through high-throughput sequencing and bioinformatics analysis, the high-abundance sgRNA and the corresponding target gene are determined, and the protein expressed by the target gene is the regulatory factor involved in regulating the activation of NLRP3 inflammasome.

8. The method according to claim 7, characterized in that The method further comprises the step of determining a suitable MOI value for virus particle infection.

9. A construction composition, characterized in that The construction composition comprises: (Z1) an inducible viral vector, wherein the inducible viral vector comprises a coding sequence for a NLRP3 mutant protein; (Z2) packaging plasmid; and (Z3) Envelope protein particle.

10. Use of the genetically engineered cell according to claim 3 and the constructed composition according to claim 9, characterized in that: Used for: (a) Induced expression of NLRP3 mutant protein; (b) screening for NLRP3 targeted inhibitors; and / or (c) Screening of regulatory factors involved in regulating NLRP3 inflammasome activation.